The Role of Telavancin in Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia

Christian E Sandrock, Andrew F. Shorr

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Hospital-acquired pneumonia (HAP) due to gram-positive pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) continues to be a major cause of morbid conditions and death. Telavancin is a lipoglycopeptide antibiotic with potent in vitro activity against a range of gram-positive pathogens, including MRSA, methicillin-susceptible S. aureus, and Streptococcus species. In 2 phase 3 clinical trials, telavancin was noninferior to vancomycin in patients with HAP due to gram-positive pathogens. Clinically evaluable patients with S. aureus as the sole pathogen or S. aureus with a vancomycin minimum inhibitory concentration >1 μg/mL, however, had higher cure rates with telavancin than with vancomycin. In patients with bacteremic HAP, telavancin resulted in clearance of blood cultures. It was associated with increased serum creatinine levels and higher mortality rates in patients with moderate to severe renal impairment at baseline; however, on subsequent analysis, the outcomes seemed to have been at least partially affected by the adequacy of empiric gram-negative antimicrobial therapy. Thus, clinicians need to consider the risk-benefit balance when choosing telavancin in patients with severe renal impairment at baseline. Overall, these data support the use of telavancin in the treatment of HAP due to S. aureus, including MRSA and strains with elevated vancomycin minimum inhibitory concentrations, but clinicians should always weigh the risks and benefits of various treatment options.

Original languageEnglish (US)
Pages (from-to)S79-S86
JournalClinical Infectious Diseases
Volume61
DOIs
StatePublished - Sep 15 2015

Fingerprint

Ventilator-Associated Pneumonia
Pneumonia
Vancomycin
Staphylococcus aureus
Methicillin-Resistant Staphylococcus aureus
Microbial Sensitivity Tests
Kidney
Phase III Clinical Trials
Methicillin
Streptococcus
telavancin
Creatinine
Therapeutics
Anti-Bacterial Agents
Mortality
Serum

Keywords

  • hospital-acquired pneumonia
  • telavancin
  • vancomycin
  • ventilator-associated pneumonia

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Cite this

The Role of Telavancin in Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia. / Sandrock, Christian E; Shorr, Andrew F.

In: Clinical Infectious Diseases, Vol. 61, 15.09.2015, p. S79-S86.

Research output: Contribution to journalArticle

@article{8ec1845c6f184a0f966a6496dea9e37b,
title = "The Role of Telavancin in Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia",
abstract = "Hospital-acquired pneumonia (HAP) due to gram-positive pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) continues to be a major cause of morbid conditions and death. Telavancin is a lipoglycopeptide antibiotic with potent in vitro activity against a range of gram-positive pathogens, including MRSA, methicillin-susceptible S. aureus, and Streptococcus species. In 2 phase 3 clinical trials, telavancin was noninferior to vancomycin in patients with HAP due to gram-positive pathogens. Clinically evaluable patients with S. aureus as the sole pathogen or S. aureus with a vancomycin minimum inhibitory concentration >1 μg/mL, however, had higher cure rates with telavancin than with vancomycin. In patients with bacteremic HAP, telavancin resulted in clearance of blood cultures. It was associated with increased serum creatinine levels and higher mortality rates in patients with moderate to severe renal impairment at baseline; however, on subsequent analysis, the outcomes seemed to have been at least partially affected by the adequacy of empiric gram-negative antimicrobial therapy. Thus, clinicians need to consider the risk-benefit balance when choosing telavancin in patients with severe renal impairment at baseline. Overall, these data support the use of telavancin in the treatment of HAP due to S. aureus, including MRSA and strains with elevated vancomycin minimum inhibitory concentrations, but clinicians should always weigh the risks and benefits of various treatment options.",
keywords = "hospital-acquired pneumonia, telavancin, vancomycin, ventilator-associated pneumonia",
author = "Sandrock, {Christian E} and Shorr, {Andrew F.}",
year = "2015",
month = "9",
day = "15",
doi = "10.1093/cid/civ535",
language = "English (US)",
volume = "61",
pages = "S79--S86",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - The Role of Telavancin in Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia

AU - Sandrock, Christian E

AU - Shorr, Andrew F.

PY - 2015/9/15

Y1 - 2015/9/15

N2 - Hospital-acquired pneumonia (HAP) due to gram-positive pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) continues to be a major cause of morbid conditions and death. Telavancin is a lipoglycopeptide antibiotic with potent in vitro activity against a range of gram-positive pathogens, including MRSA, methicillin-susceptible S. aureus, and Streptococcus species. In 2 phase 3 clinical trials, telavancin was noninferior to vancomycin in patients with HAP due to gram-positive pathogens. Clinically evaluable patients with S. aureus as the sole pathogen or S. aureus with a vancomycin minimum inhibitory concentration >1 μg/mL, however, had higher cure rates with telavancin than with vancomycin. In patients with bacteremic HAP, telavancin resulted in clearance of blood cultures. It was associated with increased serum creatinine levels and higher mortality rates in patients with moderate to severe renal impairment at baseline; however, on subsequent analysis, the outcomes seemed to have been at least partially affected by the adequacy of empiric gram-negative antimicrobial therapy. Thus, clinicians need to consider the risk-benefit balance when choosing telavancin in patients with severe renal impairment at baseline. Overall, these data support the use of telavancin in the treatment of HAP due to S. aureus, including MRSA and strains with elevated vancomycin minimum inhibitory concentrations, but clinicians should always weigh the risks and benefits of various treatment options.

AB - Hospital-acquired pneumonia (HAP) due to gram-positive pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) continues to be a major cause of morbid conditions and death. Telavancin is a lipoglycopeptide antibiotic with potent in vitro activity against a range of gram-positive pathogens, including MRSA, methicillin-susceptible S. aureus, and Streptococcus species. In 2 phase 3 clinical trials, telavancin was noninferior to vancomycin in patients with HAP due to gram-positive pathogens. Clinically evaluable patients with S. aureus as the sole pathogen or S. aureus with a vancomycin minimum inhibitory concentration >1 μg/mL, however, had higher cure rates with telavancin than with vancomycin. In patients with bacteremic HAP, telavancin resulted in clearance of blood cultures. It was associated with increased serum creatinine levels and higher mortality rates in patients with moderate to severe renal impairment at baseline; however, on subsequent analysis, the outcomes seemed to have been at least partially affected by the adequacy of empiric gram-negative antimicrobial therapy. Thus, clinicians need to consider the risk-benefit balance when choosing telavancin in patients with severe renal impairment at baseline. Overall, these data support the use of telavancin in the treatment of HAP due to S. aureus, including MRSA and strains with elevated vancomycin minimum inhibitory concentrations, but clinicians should always weigh the risks and benefits of various treatment options.

KW - hospital-acquired pneumonia

KW - telavancin

KW - vancomycin

KW - ventilator-associated pneumonia

UR - http://www.scopus.com/inward/record.url?scp=84941567513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941567513&partnerID=8YFLogxK

U2 - 10.1093/cid/civ535

DO - 10.1093/cid/civ535

M3 - Article

C2 - 26316561

AN - SCOPUS:84941567513

VL - 61

SP - S79-S86

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

ER -